StockData
AngioDynamics Inc logo

AngioDynamics Inc (ANGO) stock analysis

ANGONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 8, 2026Score 12/306% below fair value
$12.42+0.35 (+2.90%)

Close on Nov 11, 2026Market cap $522.32MP/E –Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value2Growth2Performance3Health5Dividend0

Mixed12 of 30 checks passed

AngioDynamics passes 12 of the 30 checks behind our score; 11 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
2/6
Growth
2/6
Past performance
3/6
Financial health
5/6
Dividend
0/6

What stands out

  • Trading below fair value

    The share price of $12.42 is below our fair value estimate of $13.23.

  • No debt

    AngioDynamics has no borrowings on its latest balance sheet.

  • Interest well covered

    No meaningful interest expense to cover.

  • Debt covered by cash flow

    There is no debt to cover.

What to watch

  • Margin of safety under 20%

    The price is 6.1% below fair value, less than the 20% cushion we look for.

  • Return on equity under 15%

    Return on equity was -19.2% over the last twelve months and averaged -24.1% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -21.4%, below the 10% that usually covers the cost of capital.

  • Revenue growing under 10% a year

    Revenue grew -1.9% a year over the last three fiscal years, short of the 10% we look for.

Valuation2/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B below the industry

    AngioDynamics's price-to-book of 3.19 is below the Surgical, Medical, and Dental Instruments and Supplies median of 3.20.

  • Trading below fair value

    The share price of $12.42 is below our fair value estimate of $13.23.

  • Margin of safety under 20%

    The price is 6.1% below fair value, less than the 20% cushion we look for.

Growth2/6

  • Revenue growing under 10% a year

    Revenue grew -1.9% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew 8.2% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 11.0%.

  • Guidance raised

    AngioDynamics raised its fiscal year 2026 Net Sales outlook on Apr 2, 2026.

  • Gross margin improving

    Gross margin was 55.7% over the last twelve months, against 54.1% a year earlier.

Past performance3/6

  • Return on equity under 15%

    Return on equity was -19.2% over the last twelve months and averaged -24.1% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -21.4%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    AngioDynamics's return on equity of -19.2% is above the Surgical, Medical, and Dental Instruments and Supplies median of -32.4%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was -10.1% over the last twelve months, against a 5-year average of -21.5%.

  • Net margin above the industry

    AngioDynamics's net margin of -10.1% is above the Surgical, Medical, and Dental Instruments and Supplies median of -14.1%.

Financial health5/6

  • No debt

    AngioDynamics has no borrowings on its latest balance sheet.

  • Debt not rising

    With no debt today, leverage cannot have risen.

  • Debt covered by cash flow

    There is no debt to cover.

  • Interest well covered

    No meaningful interest expense to cover.

  • Short-term assets cover short-term debts

    Current assets are 2.40 times current liabilities.

  • Bankruptcy risk in the grey zone

    The Altman Z-score is 2.54; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    AngioDynamics has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

Our estimate per share

$13.23

The share price is 6% below this estimate.

20%+ below
Near fair value
20%+ above
$12.42Price
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/B2.5×1.9×3.2×$9.9250%
P/S2.1×1.5×2.8×$16.5350%
Fair value$13.23100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Surgical, Medical, and Dental Instruments and Supplies median 27.7

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Medium risk

Average value traded per day
$11.00M
Value traded per 1% price move
$4.48M

Downside

High risk

Typical loss in a bad month
26.3%
Volatility (annualized)
48%
Sharpe ratio, 1 year
-0.07
Beta to the S&P 500 (5Y)
0.34

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2012 to 2026

Gross margin

54.6%+0.7 pts over 5 years

Operating margin

-12.5%−0.3 pts over 5 years

Net margin

-11.5%−0.6 pts over 5 years

See a number that looks wrong?